42P TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): Association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC

ESMO Open 2026 Open access

Read full text
Authors: J. Sands, A.E. Lisberg, X. Le, E. Shum, L. Hendriks, H.A. Yu, J.W. Riess, Y. Goto, Z. Piotrowska, K.H. Tang, J. Harper, S. Pölsterl
+8 more H.J. Failmezger, D. Vonficht, Rachel Chiaverelli, J.M. Lehman, P.G. Fraenkel, H. Zebger-Gong, S.B. Goldberg, M-J. Ahn
DOI: 10.1016/j.esmoop.2026.106349
Cited by: 2

Abstract

Dato-DXd received accelerated US FDA approval for treatment of EGFRm NSCLC based on a pooled analysis of EGFRm cohorts from TROPION-Lung05 (TL05; NCT04484142) and TROPION-Lung01 (TL01; NCT04656652). TROP2 NMR status by QCS was associated with clinical outcomes with Dato-DXd in patients (pts) with non-squamous, non-actionable genomic alteration (NSQ non-AGA) NSCLC who were treated in TL01 and TROPION-PanTumor01 (NCT03401385). Here we report data assessing TROP2 NMR status in pts with EGFRm NSQ NSCLC receiving Dato-DXd in TL01 and TL05 or osi + Dato-DXd in the ORCHARD study (NCT03944772).

Fields of Study & Subjects

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Colorectal Cancer Treatments and Studies

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
106349–106349
Publication date
17 March 2026
Language
EN